Skip to content
StockMarketAgent
Direct answer
ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $411, high $854, with mid-point at $632.
Stock analysis

ELV ELV fair value $411–$854

ELV
By StockMarketAgent.AI team· supervised by
Geanalyseerd: 2026-05-13Volgende update: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Koers
$381.75
▲ +250.57 (+65.64%)
Fair value
$632
$411–$854
Beoordeling
Sterk kopen
confidence 77/100
Opwaarts potentieel
+65.6%
upside to fair value
Veiligheidsmarge
$537.47
MoS level · 15%
Marktkapitalisatie
$82.9B
P/E fwd 13.1
Engelse bronNL
Engelse bron wordt weergegeven terwijl we vertalen
Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.

§1 Samenvatting

  • Composite fair value $632 with high case $854.
  • Implied upside of 65.6% to fair value.
  • Moat 9/10 · confidence 77/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$632
Margin of safety
+39.6%
Confidence
77/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$381.75Price
Low $411.38
Mid $632.32
High $853.64

ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Scale advantages driven by a
    Scale advantages driven by a massive member base in Anthem.
  • Network effects within the integrated
    Network effects within the integrated Anthem and Carelon ecosystems.
  • Bull thesis
    Massive margin of safety with implied -6.18% perpetual growth at the current price.

§2 Berenscenario

A severe scenario where elevated MLR persists due to structural shifts in medical utilization, compounded by adverse Medicare rate changes, significantly compressing operating margins below their historical norms.

Hoe deze these kan breken

Unchecked Medical Cost Inflation

· Medium

Sustained elevated medical utilization drives MLR structurally higher, compressing operating margins permanently below historical averages.

FV impact
-35%
Trigger
12-24 Months

Severe Regulatory Reimbursement Cuts

· Low

Aggressive legislative action slashes Medicare Advantage and Medicaid reimbursement rates, effectively stunting top-line growth.

FV impact
-25%
Trigger
24-36 Months

Carelon Growth Stagnation

· Medium

Intense PBM competition limits Carelon's ability to win new external mandates, stalling the long-term margin-expansion thesis.

FV impact
-15%
Trigger
12-18 Months
Vroege waarschuwingssignalen om te volgen
MetriekHuidigTrigger-drempel
Medical loss ratio sequentially rising above targeted corridors.MonitorDeterioration versus the report thesis
Regulatory announcements of tighter Medicare funding.MonitorDeterioration versus the report thesis
Stalling growth or mandate losses in the Carelon segment.MonitorDeterioration versus the report thesis
Operating margins dipping below the 5.0% normalized threshold.MonitorDeterioration versus the report thesis
Material reduction in projected share repurchase pacing.MonitorDeterioration versus the report thesis

§3 Financiële historie

Winst-en-verliesrekening — laatste zes perioden
PostT−0T−1T−2T−3T−4CAGR
Periode2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Omzet$156.60B$171.34B$176.81B$199.13B+6.2%
Brutowinst
Bedrijfsresultaat
Nettowinst$5.89B$5.99B$5.98B$5.66B-1.0%
WPA (verwaterd)$24.81$25.22$25.68$25.21+0.4%
EBITDA
R&D
VAA$15.91B$17.69B+2.7%

Kwaliteitsscores

OCF / Nettowinst
0.76×
>1 wijst op hoge winstkwaliteit
Drempel boekhoudkwaliteit
Fail
Sector-aangepaste drempel
ROIC
8.4%
Rendement op geïnvesteerd kapitaal
Sectie 3

Numbers analysis

Kasstroom

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Kapitaalallocatie

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Individuele abonnees — vanaf §411 extra secties

Lees de volledige analyse — 11 extra secties.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Volledig rapport voor elke gedekte ticker
24 maanden rating-archief
Watchlist-briefings + rating-wijzigingsmeldingen
PDF + DOCX-export in elke taal
Start gratis proefperiode
Op elk moment opzegbaar.
FAQ

ELV — frequently asked questions

  1. Based on our latest analysis, ELV looks meaningfully undervalued. The current price is $382 versus a composite fair-value midpoint of $632 (range $411–$854), which implies roughly 65.6% upside to the midpoint.
Related coverage

Names readers of ELV also follow

Same archetype: mature-compounder